Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Gains from Investment Securities data on record, last reported at -$2.0 million in Q2 2025.

  • For Q2 2025, Gains from Investment Securities fell 483.24% year-over-year to -$2.0 million; the TTM value through Sep 2025 reached -$58.1 million, down 7601.42%, while the annual FY2024 figure was $2.9 million, 366.92% up from the prior year.
  • Gains from Investment Securities reached -$2.0 million in Q2 2025 per CRVS's latest filing, up from -$25.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $971000.0 in Q2 2023 and bottomed at -$31.0 million in Q4 2024.
  • Average Gains from Investment Securities over 4 years is -$4.7 million, with a median of $41200.0 recorded in 2022.
  • The widest YoY moves for Gains from Investment Securities: up 1087.85% in 2023, down 10380.0% in 2023.
  • A 4-year view of Gains from Investment Securities shows it stood at $10000.0 in 2022, then plummeted by 10380.0% to -$1.0 million in 2023, then crashed by 2915.08% to -$31.0 million in 2024, then surged by 93.51% to -$2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$2.0 million in Q2 2025, -$25.1 million in Q1 2025, and -$31.0 million in Q4 2024.